Allozyne has attracted leaders in protein engineering, biochemistry and molecular biology to our Scientific Advisory Board. Our Interferon Advisory Board comprises scientists and clinicians who have played leading roles in developing and commercializing interferon-based therapies for the treatment of cancer and multiple sclerosis. These advisors are a critical, competitive asset as we strive to build an efficient and robust R&D organization that will benefit patients and our investors.
Scientific Advisory Board
David A. Tirrell, Ph.D.
Ross McCollum-William H. Corcoran Professor and Professor of Chemistry and Chemical Engineering Chair, Division of Chemistry and Chemical Engineering, California Institute of Technology
David A. Tirrell, Ph.D., received his B.S. and Ph.D. degrees from MIT and the University of Massachusetts, respectively. Dr. Tirrell was an assistant professor in the Department of Chemistry at Carnegie-Mellon University, and then returned to the University of Massachusetts, where he was Director of the Materials Research Laboratory and Barrett Professor of Polymer Science and Engineering. Dr. Tirrell currently serves as Division Chair for Chemistry and Chemical Engineering at Caltech. He has served as Visiting Professor at the University of Queensland, at the Institut Charles Sadron in Strasbourg, at the University of Wisconsin-Madison, and at the Institut Curie in Paris. Dr. Tirrell is a Fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. Dr. Tirrell was Editor of the Journal of Polymer Science, Part A: Polymer Chemistry, and has served on the editorial boards of Macromolecules, ChemBioChem, Accounts of Chemical Research, Chemical and Engineering News, and several other journals. Dr. Tirrell chaired the 1994 Gordon Research Conference on Polymers in Biosystems and the 1995 Gordon Conference on Chemistry of Supramolecules and Assemblies.
William Goddard, Ph.D.
Founder, Allozyne, Inc.
Charles and Mary Ferkel Professor of Chemistry, Materials Science, and Applied Physics and Director of Materials and Process Simulation Center, California Institute of Technology
William Goddard, Ph.D., received his B.S. degree with Hightest Honors from the University of California, Los Angles, and his Ph.D. in Engineering Science (with a minor in Physics) from the California Institute of Technology (CalTech). Since 1978, Dr. Goddard has had a distinguished career at CalTech, with appointments to the position of Professor of Chemistry and Applied Physics and Professor of Theoretical Chemistry. He has been Director of both the National Science Foundation (NSF) Materials Research Group and the NSF Grand Challenge Application Group at CalTech. Since 1990, Dr. Goddard has served as Director of Materials and Process Simulation Center (MSC) at Caltech and, since 2001 he has been the Charles and Mary Ferkel Professor of Chemistry, Materials Science and Applied Physics. Dr. Goddard has authored more than 735 research publications and currently receives research funding from leading government and industry organizations, including: NSF, National Institutes of Health, Department of Energy, Defense Advanced Research Projects Agency, Army Research Office, Office of Naval Research, Environmental Protection Agency, Chevron, Intel Corp., Dow-Corning, Pfizer, Boehringer-Ingelheim and Allozyne.
Dr. Goddard has received numerous awards and honors, including: the American Chemical Society Award for Computers in Chemistry (1988), the Feynman Prize for Nanotechnology Theory (1999), the American Chemical Society Award for Theoretical Chemistry (2007) and the NASA Space Sciences Award (2000 and 2007). He has served as a consultant to diverse multinational companies, including: General Electric, General Motors, Shell Development, BP, Exxon, Chevron, Dow Chemical, AT&T Bell Labs, Union Carbide, 3M, Proctor and Gamble, Dow Corning and Nissan. Dr. Goddard also has co-founded five companies: Molecular Simulations Inc. (now Accelrys), Schrödinger Inc., Eidogen Inc. (now Eidogen-Sertanty), Systine Inc. and, most recently, Allozyne Inc.
Harvey F. Lodish, Ph.D.
Member, Whitehead Institute for Biomedical Research and Professor of Biology and Professor of Bioengineering, Massachusetts Institute of Technology, Cambridge, MA
Harvey Lodish, Ph.D., received his A.B. degree Summa Cum Laude and with Highest Honors in Chemistry and Mathematics, from Kenyon College, and his Ph.D. degree in genetics with Dr. Norton Zinder from the Rockefeller University. He continued post-doctoral work at the M.R.C. Laboratory of Molecular Biology with Drs. Sydney Brenner and Francis Crick. He currently serves as a Professor at MIT and the Whitehead Institute for Biomedical Research.
Dr. Lodish has served on advisory panels for the NIH, NSF, and American Cancer Society, and on the advisory boards of several institutions, including the Biozentrum of the University of Basle, the European Molecular Biology Laboratory in Heidelberg, the Center for Molecular Biology Heidelberg (ZMBH) in Germany, and the PEW Scholars Program in Biomedical Sciences. He was chair of the advisory board of the Division of Basic Sciences of the Fred Hutchinson Cancer Center and of the Cleveland Clinic Lerner Research Institute and is currently Chair of the Scientific Advisory Board of Children’s Hospital, Boston. He is currently a member of the Board of Trustees of Kenyon College and of Children’s Hospital, Boston. He also serves on the Visiting Committee of the California Institute of Technology Division of Biology. He currently is a member of the Board of Trustees of Kenyon College and of Children’s Hospital, Boston. He also serves on the Visiting Committee of the California Institute of Technology Division of Biology.
Dr. Lodish is a member of the National Academy of Sciences. He was a founder and scientific advisory board member of Genzyme, Inc., Arris Pharmaceuticals, Inc, and Millennium Pharmaceuticals, Inc. He previously served on the Scientific Advisory Board of Astra and then AstraZeneca Pharmaceuticals and of the Eisai Research Institute.
K. Barry Sharpless, Ph.D.,
W.M. Keck Professor of Chemistry, The Scripps Research Institute
Barry Sharpless, Ph.D., received his B.S. degree from Dartmouth College and his Ph.D. from Stanford University. He completed post-doctoral studies with J.P. Collman at Stanford and with Konrad Bloch at Harvard. In 1970, Dr. Sharpless was appointed to the position of Assistant Professor at the Massachusetts Institute of Technology (MIT). For several years in the 1970s, Dr. Sharpless was a member of Stanford’s Chemistry faculty, subsequently returning to MIT, where he remained until 1990. At that time, he joined the faculty of the Scripps Research Institute (TSRI), where today he is the W. M. Keck Professor of Chemistry and a member of the Skaggs Institute for Chemical Biology.
In 2001, Dr. Sharpless shared the Nobel Prize in Chemistry with William S. Knowles and Ryoji Noyori for their work on chemical synthesis reactions. His Nobel Prize citation says, “many scientists have identified Sharpless’s epoxidation [discovered with Tsutomu Kastsuki in 1980] as the most important discovery in the field of synthesis during the past few decades.”
Today, Dr. Sharpless continues to pursue new methods for selectively controlling chemical reactions. A recent advance is “Click Chemistry” a set of powerful, selective reactions that enable the rapid synthesis of new compounds. Click chemistry is an integral part of research in Dr. Sharpless’s lab at TSRI and has provided a foundation for numerous collaborations with biologists at TSRI and at other leading research organizations.
Leroy Hood, Ph.D.
President, Institute for Systems Biology
Leroy Hood, M.D., Ph.D., is co-founder and President of the Institute for Systems Biology (ISB) in Seattle, Washington. Dr. Hood's research has focused on the study of molecular immunology, biotechnology, and genomics. Prior to his work at the ISB, Dr. Hood was the founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology at the University of Washington. Dr. Hood began his professional career at Caltech where he and his colleagues pioneered four instruments — the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer — which comprise the technological foundation for contemporary molecular biology. Dr. Hood has also played a role in founding numerous biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He has published more than 500 peer-reviewed papers, received 14 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics, and is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, and the Institute of Medicine.
Interferon Advisory Board
David A. Hafler, M.D.
Sadie and David Breakstone Professor of Neurology (Neuroscience), Harvard Medical School; Physician at the Brigham and Women’s Hospital and the Massachusetts General Hospital
David A. Halfer, M.D., received his B.S. and M.Sc. degrees in biochemistry from Emory University and his M.D. degree the University of Miami School of Medicine. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York. Dr. Hafler received training in immunology at the Rockefeller University then at Harvard where he joined the faculty in 1984. He is a member of the Program in Immunology at Harvard Medical School and is on the faculty of the Harvard-MIT Health Science and Technology program. Dr. Hafler also leads the NIH Autoimmunity Prevention Center Grant at Harvard, and is a Jacob Javits Merit Award Recipient from the National Institutes of Health (NIH). Dr. Hafler has been elected to membership in the American Society of Clinical Investigation, The American Neurological Association, the Alpha Omega Society, and was a Harvey Weaver Scholar of the National Multiple Sclerosis Society. He is currently a member of the editorial boards for Journal of Clinical Investigation, Cellular Immunology, Clinical Immunology, and Journal of Neuroimmunology, and is co-founder of the Federation of Clinical Immunology Societies. He also heads the Division of Molecular Immunology in the Center for Neurologic Diseases, Harvard Medical School.
Dr. Hafler’s clinical research is focused on understanding the mechanism of autoimmunity with a particular interest in inflammatory central nervous system diseases, and he has more than 270 publications in the field of autoimmunity and immunology. He is an Associated Member of the Broad Institute, where he is heading an initiative to solve the genetic basis of multiple sclerosis. He recently received the 1st National Multiple Sclerosis five-year Collaborative Center Award with Dr. Eric Lander of the Broad Institute for tackling the multiple sclerosis (MS) genetic effort. Dr. Hafler is a founding member of the International MS Genetic Consortium, a group recently formed to define the genetic causes of MS.
Whaijen Soo, Ph.D.,
Whaijen Soo, Ph.D., is Senior Vice President, Research and Development at Shire Human Genetic Therapies (HGT). In this position, Dr. Soo is responsible for overseeing HGT’s strategic planning and growth and management of its research and development portfolio. He also plays a key role in assessing and capturing business development opportunities. Dr. Soo’s functional group includes preclinical research and development, clinical research, regulatory affairs, process development, and medical affairs.
Prior to joining Shire HGT, Dr. Soo was Senior Vice President, Medical Research, at BiogenIdec, where he was responsible for the worldwide clinical development of all drugs in the company’s portfolio. Functionally, his organization included clinical operations, drug safety and risk management, biometrics and medical writing, as well as therapeutic-area groups in neurobiology, immunology-rheumatology, and oncology. His teams were responsible for the successful filings of a number of New Drug Applications (NDAs) and Investigational New Drug (IND) applications with regulatory agencies in the United States, Europe and rest of the world.
Before joining BiogenIdec, Dr. Soo spent eighteen years with Hoffmann La-Roche Inc., as Vice President and head of clinical sciences in charge of worldwide clinical development of new anticancer drugs, antiviral and immunotherapies against AIDS and other viral diseases, as well as drugs used for transplantation. Under his leadership, Roche successfully submitted and received market registration of fifteen new drug or biologics applications and line extensions. In particular, he built the global oncology portfolio from two drugs in the portfolio and three physicians into a group with more than ten drugs in development and over fifty physicians, clinical research scientists and specialists. He also created a Genetics and Integrated Medicine Unit for a coordinated effort on pharmacogenomics. He has coordinated business and research strategic planning, as well as pharma portfolio management at Roche, and led the integration of clinical research organizations during Roche’s acquisitions of Syntex and Bohringer-Mannheim.
Dr. Soo was a member of numerous public and trade committees, including Round Table on Research and Development of Drugs, Biologics, and Devices, Institute of Medicine, National Academy of Science, Board of Participants, Intercompany Collaborations on AIDS drug development, and Scientific Panel, American Foundation on AIDS Research. He is a board member of Linden Technologies Inc.
Dr. Soo received his Ph.D. in Biochemistry from the University of California, Berkeley and his M.D. from the University of California, San Francisco. He also completed postgraduate training at Brigham and Women’s Hospital, Harvard Medical School, in Boston.
Alexander R. Giaquinto, Ph.D.
Most recently, Dr. Giaquinto was Senior Vice President for Global Compliance at Schering-Plough Corporation, until his retirement in 1994. In more than 30 years at Schering Plough, Dr. Giaquinto held numerous positions, including Director of Regulatory Affairs and Senior Vice President of Worldwide Regulatory Affairs. During his tenure, Dr. Giaquinto was instrumental in establishing the Development and Regulatory strategies for the approvals of 74 New Drug Applications (NDA), which included such major products as Proventil, Vanceril, Vancenase, Rebetrol, Claritin, Claritin-D, Clarinex, Elocon, Integrilin, Temodar, Asmanex and Zetia; 9 Biologic Licensing Applications (BLA), including Intron, Peg-Intron and Rebetron; and 28 Abbreviated New Drug Applications (ANDA). In addition, he was instrumental in establishing the Rx to OTC strategies for Chlortrimeton, Drixoral, Lotrimin, Gyne-Lotrimin and Claritin.
Dr. Giaquinto’s also has participated in numerous professional organization and events. He served as a member and chairman of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers Association and was one of the original members to the Steering Committee of the International Conference of Harmonization (ICH) and served as one of the two U.S. Pharmaceutical Industry representatives from 1990 to 2003. While serving on the ICH Steering Committee, he introduced the concept of the Common Technical Document (CTD) and served as Co-chair of both the Common Technical Document Implementation Coordination Group and the Global Cooperation Group. Dr. Giaquinto also is a member of the American Pharmaceutical Association, the American Association of Pharmaceutical Sciences, the American Society of Clinical Pharmacology and Therapeutics, the New York Academy of Sciences and the Drug Information Association.
Dr. Giaquinto has been a lecturer on Food and Drug Law at Temple University Graduate Program in Quality Assurance/Regulatory Affairs and serves on their Advisory Committee. He also serves on the Planning Committee at the University of Texas (Austin) for their Program on the International Conference for Drug Development (ICDD). Dr. Giaquinto serves on the Board of Directors for SemBioSys – Genetics and the Advisory Board for Avaan Therapeutics. Dr. Giaquinto is Vice Chairman of the Board of Trustees for Caldwell College, where he currently serves on both the Development and Audit Committees. Dr. Giaquinto also serves on both the Foundation and the Hospital Boards of Children’s Specialized Hospital Foundation, and has served as the Chairman of Children’s Specialized Hospital Foundation Board since 2000.
Dr. Giaquinto received his B.Sc. in Pharmacy from St. John’s University and his Ph.D. in Pharmaceutics from the University of Connecticut.
Elliot I. Stupak, Ph.D.
Most recently, Dr. Stupak was Senior Vice president of Global Compliance and Quality Audits at Schering Plough Inc. During his 32 year tenure with Schering-Plough, Dr. Stupak held numerous positions including Senior Vice President of Development, with responsibility for the Biotechnology, Chemical and Pharmaceutical Development functions.
Dr. Stupak also served as Team Chairman for several projects and therapy areas, including the Interferon and Oncology Teams. Dr Stupak has been active in professional organizations during his career, including Pharma, where he served as Chairman of the Pharmaceutical Development Sub-Section. He received his B.S. in Pharmacy from Columbia University and his Ph.D. in Pharmaceutical Sciences from the University of Connecticut.
John M. Davitt
Mr. Davitt served for nearly 30 years at the U.S. Food and Drug Administration (FDA). At the FDA, Mr. Davitt was Pharmacologist, Division of Toxicological Evaluation, from 1963 to 1966 and Supervisory Pharmacologist, Division of Anti-infective Drug Products, from 1966 to 1990. In his tenure at the FDA, Mr. Davitt actively participated in the agency's decision-making on new drugs, formulation of policy for dealing with safety issues, and development of non-clinical toxicology guidelines. As the Supervisory Pharmacologist of FDA's Division of Anti-Infective Drug Products, he had responsibility for all non-clinical pharmacology/toxicology review of drugs falling within the Division's range of authority.
Mr. Davitt is a member of numerous professional organizations, including: the Society of Toxicology, the Association of Government Toxicologists, the Drug Information Association, the Roundtable of Toxicological Consultants and the Food and Drug Administration Alumni Association. Mr. Davitt received his B.S. in Pharmacy from Long Island University and his M.S. in Pharmacology from the University of Michigan.
